Antagonists of PD-1 and PD-L1 in Cancer Treatment

Evan J. Lipson, Patrick M. Forde, Hans Joerg Hammers, Leisha A. Emens, Janis M. Taube, Suzanne L. Topalian

Research output: Contribution to journalReview articlepeer-review

235 Scopus citations


PD-1 pathway, comprising immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer rapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. manageable safety profile of PD-1/PD-L1 blocking drugs identifies m as suitable for outpatient administration and development of combinatorial rapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would furr improve risk:benefit ratio for se drugs.

Original languageEnglish (US)
Pages (from-to)587-600
Number of pages14
JournalSeminars in oncology
Issue number4
StatePublished - Aug 1 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Antagonists of PD-1 and PD-L1 in Cancer Treatment'. Together they form a unique fingerprint.

Cite this